An interventional study of RINCE in Fibromyalgia, sponsored by Cerephex Corporation. Completed at 1 site in United States. Open to participants aged 22 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-09-17.
Sponsored by Cerephex Corporation · Not applicable, Interventional, and Treatment
The purpose of this open label study is to provide up to 24 active treatments of noninvasive cortical electrostimulation therapy only to those fibromyalgia patients who experienced inadequate pain reduction in a sham controlled double blinded lead in study, NPT-201 (NCT01825954). The therapy will be provided by the NeuroPoint device using the same protocol as that used in active treatment arms of NPT-201. The study's primary outcome measure will be the patient's change from baseline in self-reported 24-hour average pain intensity. The study will provide active treatment to those participants who received sham therapy in NPT-201, and will test whether or not additional therapy applications might further improve pain in those participants who previously received active therapy, but did not achieve adequate pain relief.
1,335 studies on the registry are indexed under Fibromyalgia; 265 are open to participants now.
This study's enrollment of 23 is below the median of 60 across 1,034 interventional studies indexed under Fibromyalgia.
Browse Fibromyalgia studies →Cerephex Corporation is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
RINCE - active RINCE therapy involving 24 total treatment applications from the NeuroPoint device
Device: RINCE
The NeuroPoint device is used to deliver repeat applications of RINCE therapy
Also known as: RINCE therapy, RINCE therapy using the NeuroPoint device
Change from baseline in patient 24-hour recall average pain intensity
Pain intensity evaluated on a 100-mm visual analog scale (VAS)
Time frame: Assessed at 12 weeks
Patient self-reported Global Impression of Change
Time frame: Assessed at 12 weeks
Change from baseline in Revised Fibromyalgia Impact Questionnaire
Time frame: Assessed at 12 weeks
Change from baseline in patient 7-day recall average pain intensity
Time frame: Assessed at 12 weeks
Change from baseline in Jenkins Sleep Questionnaire
Time frame: Assessed at 12 weeks
Change from baseline in Beck Depression Inventory (BDI-II)
Time frame: Assessed at 12 weeks
This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cerephex Corporation